Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00203385 · ClinicalTrials.gov registry record · Phase 4

Maintenance Phase Treatment With Divalproex for Post Traumatic Stress Disorder

A Phase 4 study, sponsored by Tuscaloosa Research & Education Advancement Corporation.

Terminated
Registry status
Phase 4
Development phase
20
Enrollment target

NCT00203385 is a Phase 4 study that was terminated before completion, run by Tuscaloosa Research & Education Advancement Corporation. The registered enrollment target is 20 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00203385, a Phase 4 study, was terminated before completion, sponsored by Tuscaloosa Research & Education Advancement Corporation.

TERMINATED
Registry status
Phase 4
Development phase
20 participants
Enrollment target

Study Summary

The primary objective is to evaluate the long-term efficacy of divalproex sodium (Depakote) in the continuation treatment of PTSD.

Interventions

  • DRUG Divalproex

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2003-05
Est. Completion 2005-03
Phase Phase 4

What the Registry Record Tells You About NCT00203385

The ClinicalTrials.gov registry entry for NCT00203385 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tuscaloosa Research & Education Advancement Corporation, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Divalproex is the first listed.

NCT00203385 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00203385 about?

NCT00203385 is a clinical study titled "Maintenance Phase Treatment With Divalproex for Post Traumatic Stress Disorder". The primary objective is to evaluate the long-term efficacy of divalproex sodium (Depakote) in the continuation treatment of PTSD.

What is the current status of trial NCT00203385?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2003-05. Estimated completion is 2005-03.

What interventions are being tested in trial NCT00203385?

The interventions under investigation include: Divalproex (DRUG).

Who is sponsoring clinical trial NCT00203385?

This trial is sponsored by Tuscaloosa Research & Education Advancement Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.